HOME >> MEDICINE >> NEWS
Drug aimed at Huntington's eases chorea, the disease's hallmark feature

A drug widely available in Europe and Canada but not the United States dramatically eases one of the most disabling symptoms of Huntingtons disease, involuntary writhing movements known as chorea, according to a study in the Feb. 14 issue of the journal Neurology.

The medication, tetrabenazine, is currently being reviewed by the U.S. Food and Drug Administration. If approved, the medication would be the first authorized by the agency expressly for the treatment of Huntingtons disease, which affects about 30,000 people in the United States.

In a randomized, controlled study conducted in 84 patients at 16 sites around the nation, doctors found that the medication cut down involuntary movement on average by about 25 percent, with many patients experiencing a greater improvement. Overall, patients who received the medication were six times as likely to be considered by their doctors to have improved considerably, compared to participants who received a placebo.

Neuroleptic drugs like haloperidol (Haldol) are currently in widespread use in the United States to suppress chorea, but the effect of these drugs on chorea has never been studied in a systematic way, and they have a number of troublesome side effects, such as blunting of personality, loss of voluntary movement, and hindering balance. Our study showed that tetrabenazine, when appropriately dosed, can decrease chorea without causing those side effects, said Frederick J. Marshall, M.D., a neurologist at the University of Rochester Medical Center who led the study conducted by the Huntington Study Group. The study was funded by Prestwick Pharmaceuticals of Washington, D.C., the company that owns the rights to develop and sell the medication in the United States.

Tetrabenazine was originally developed in the 1950s to treat psychosis, but was quickly pushed aside by more effective medications. But doctors in the United Kingdom found it to be effective to treat the excessive involuntar
'"/>

Contact: Tom Rickey
tom_rickey@urmc.rochester.edu
585-275-7954
University of Rochester Medical Center
13-Feb-2006


Page: 1 2 3 4

Related medicine news :

1. Science of healthy foods subject of grant aimed at university students
2. Drug ads aimed at cancer patients difficult to read, make more appeals to effectiveness than safety
3. Cardiovascular flow disturbances study aimed at improving diagnosis and treatment
4. Endocrinologist-directed intervention aimed at primary care physicians improves diabetes care
5. New technology to speed up research into Huntingtons disease
6. Study identifies possible mechanism for brain damage in Huntingtons disease
7. Study identifies potential drug target for Huntingtons disease
8. Neural transplants provide persistent benefit in patients with Huntingtons disease
9. Rush designated Center of Excellence by Huntingtons Disease Society of America
10. A broader look at cardiac CTA images often finds diseases/disorders beyond the heart
11. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/3/2016)... ... May 03, 2016 , ... Sandbox, one of the nation’s ... in the newly created position of executive vice president, chief creative officer.     , ... the Chicago and LA offices. He reports to Nancy Finigan, president of those ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... pharmacies, will be represented at the 2016 Asembia Specialty Pharmacy Summit held May ... is the largest U.S. health care conference for the specialty pharmacy industry, with ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... been selected by Tidelands Health, a three hospital system in South Carolina, to ... on the lookout for technology that enhances communication, drives workflow efficiencies and improves ...
(Date:5/3/2016)... ... 03, 2016 , ... Nationally recognized personal injury law firm Monge & Associates is ... to anyone who wants one for their Mother or any other mother figure. , According ... of Mothers.” Monge goes on to say, “we are choosing to do this by ...
(Date:5/3/2016)... ... , ... Ogawa World USA introduced the first of its kind Ogawa ... Application. The Smart 3D combines the best in technological advancement, design, and massage capability ... specialized massage program, each user has a tailored experience unparalleled by any other massage ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)...   BIOTRONIK will be exhibiting and initiating ... implant at the Heart Rhythm Society,s 37 th ... Francisco . "Physicians and hospitals ... patient care and satisfaction possible. Part of that process ... tomorrow," said Marlou Janssen , President, BIOTRONIK, Inc. ...
(Date:5/3/2016)... According to market research "Global ... and Demand Forecast to 2022 - Industry Insights by ... Very High Field, Low to Mid Field, and Ultra ... Musculoskeletal, Vascular, Breast, Pelvic and Abdomen, Cardiac, and Other)" ... market was valued at $5,351.7 million in 2015, and ...
(Date:5/3/2016)... -- Forté Elements, LLC (Forté) is excited to announce the launch of its Mediceutical line ... of recovery for a variety of clinical conditions. Founded in 2013, Forté spent more ... Logo -  http://photos.prnewswire.com/prnh/20160502/362547LOGO ... ... ...
Breaking Medicine Technology:
Cached News: